Entering text into the input field will update the search result below

Complementary Healthcare Analysis - 2019-08-13

Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Long/Short Equity, Healthcare, Biotech

Seeking Alpha Analyst Since 2017

Avisol Capital Partners runs the Total Pharma Tracker Seeking Alpha Marketplace service. This is managed by Dr Asok Dutta, BVScAH and Dr Udaya Kumar Maiya, MD Oncologist. The service offers end-to-end research on both investing and trading ideas everyday, and includes a 150-stock watchlist and two 40-stock model portfolios that are continuously tracked.

Dr Dutta is a retired veterinary surgeon. He has over 40 years experience in the industry. Dr Maiya is a well-known oncologist who has 30 years in the medical field, including as Medical Director of various healthcare institutions. Both doctors are also avid private investors. They are assisted by a number of finance professionals in developing this service.

If you want to check out our service, go here - https://seekingalpha.com/author/avisol-capital-partners/research

Disclaimer - we are not investment advisors.
Top Gainers
Company Market Cap Price Change% Volume
DelMar Pharmaceuticals, Inc. (DMPI) 6.24M 1.89 11.84% 3,107,971
Foamix Pharmaceuticals Ltd. (FOMX) 140.57M 2.95 10.07% 586,648
Novavax, Inc. (NVAX) 99.37M 4.35 8.21% 331,202
Acasti Pharma Inc. (ACST) - 2.05 5.13% 448,405
Top Losers
Company Market Cap Price Change% Volume
Biocept, Inc. (BIOC) 20.51M 1.03 -5.50% 663,297
Portola Pharmaceuticals, Inc. (PTLA) 2.05B 28.95 -5.48% 413,328
High volume stocks reaching new highs
Company Market Cap Price Change% Volume
Amgen Inc. (AMGN) 124.91B 209.65 1.88% 1,115,420
Genmab A/S (GMAB) 12.40B 19.68 2.82% 533,676
Baxter International Inc. (BAX) 43.66B 87.37 2.07% 331,691
High volume stocks reaching new lows
Company Market Cap Price Change% Volume
Guardion Health Sciences, Inc. (GHSI) 11.62M 0.22 -63.86% 4,632,840
Mallinckrodt plc (MNK) 469.03M 4.72 -1.97% 2,031,927
Aclaris Therapeutics, Inc. (ACRS) 38.56M 0.84 -1.03% 914,424
Major Analyst Upgrades
Company Current Rating New Rating Analyst Current Price Target Price
Avadel Pharmaceuticals (AVDL) Hold Buy Laidlaw $1.95
Axovant Gene Therapies (AXGT) Neutral Outperform Robert W. Baird $6.57 $13.00
Humana (HUM) Neutral Overweight Cantor Fitzgerald $295.50 $345.00
Zimmer Biomet (ZBH) Hold Buy Argus $138.45 $160.00
Major Analyst Downgrades
Company Current Rating New Rating Analyst Current Price Target Price
AAC (AAC) Outperform Market Perform Raymond James $0.8170
Abeona Therapeutics (ABEO) Overweight Neutral Cantor Fitzgerald $2.28
ADMA Biologics (ADMA) Buy Neutral Dawson James $3.71
Aptinyx (OTC:APTX) Neutral Underweight JPMorgan Chase & Co. $3.63
Avedro (AVDR) Outperform Market Perform Leerink Swann $21.81
bluebird bio (BLUE) Outperform Market Perform William Blair $118.65
Cambrex (CBM) Buy Hold Craig Hallum $59.99 $60.00
Clovis Oncology (CLVS) Buy Neutral Bank of America $5.67 $7.00
Melinta Therapeutics (MLNT) Buy Neutral HC Wainwright $2.64
RA Medical Systems (RMED) Overweight Neutral Cantor Fitzgerald $2.82 $2.00
Overweight Neutral Piper Jaffray Companies $2.82 $1.50
Wright Medical Group (WMGI) Outperform Market Perform Wells Fargo & Co $20.77 $23.00
Major Insider Buys
Company Insider Name Insider Title Price Qty Value
Assertio Therapeutics, Inc (ASRT) Peisert Daniel A. SVP, CFO $1.57 19000 +$29,773
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Cohen Yuval CEO $6.06 1175 +$7,116
Discordia Robert Paul COO $5.86 15000 +$87,894
Dova Pharmaceuticals Inc. (DOVA) Manning Paul B Dir, 10% $15.87 28062 +$445,344
Dynavax Technologies Corp (DVAX) Cano Francis Dir $3.00 16667 +$50,001
Novack David F Co-Pres, SVP $3.00 16667 +$50,001
Phillips Peggy V Dir $3.00 16666 +$49,998
Eton Pharmaceuticals, Inc. (ETON) Casamento Charles J Dir $6.11 3500 +$21,370
Kezar Life Sciences, Inc. (KZR) Belsky Marc CFO $4.82 500 +$2,410
Economides Vassiliki SVP, Strategy, External Aff. $4.96 1020 +$5,057
Fowler John Franklin CEO $5.11 1250 +$6,389
Kirk Christopher J. Pres, CSO $4.97 5000 +$24,830
Sarepta Therapeutics, Inc. (SRPT) Ingram Douglas S Pres, CEO $123.07 16252 +$2,000,160
Siga Technologies Inc (SIGA) Savas Paul G Dir $5.08 10000 +$50,800
Therapeuticsmd, Inc. (TXMD) Finizio Robert G CEO $2.96 52405 +$155,119
Veru Inc. (VERU) Socorro Jesus Dir $1.95 10000 +$19,506
Wright Medical Group N.V. (WMGI) Palmisano Robert J Pres, CEO $21.39 46654 +$997,742
Major Insider Sells
Company Insider Name Insider Title Price Qty Value
Avenue Therapeutics, Inc. (ATXI) Vazzano Joseph Walter CFO $5.59 -4688 -$26,204
Concert Pharmaceuticals, Inc. (CNCE) Hutt Peter Barton Dir $10.31 -3539 -$36,487
Horizon Therapeutics Public Ltd Co (HZNP) Curtis Geoffrey M. EVP, Corporate Affairs, CCO $26.58 -20609 -$547,830
Jazz Pharmaceuticals Plc (JAZZ) Berns Paul L Dir $135.65 -726 -$98,481
Enright Patrick G Dir $135.65 -726 -$98,481
Gray Peter Dir $135.65 -787 -$106,757
McSharry Heather Ann Dir $135.65 -787 -$106,756
O'Keefe Kenneth W Dir $135.65 -726 -$98,482
Riedel Norbert G Dir $135.65 -726 -$98,482
Schnee Elmar Dir $135.65 -817 -$110,825
Sohn Catherine A. Dir $135.65 -726 -$98,482
Winningham Rick E Dir $135.65 -726 -$98,482
Merck & Co., Inc. (MRK) Deluca Richard R. EVP, Pres, Merck Animal Heallt $85.02 -38126 -$3,241,639
Myokardia Inc (MYOK) Lee June EVP, Chief Development Officer $57.00 -4565 -$260,219
Spectrum Pharmaceuticals Inc (SPPI) McGahan Keith M GC $7.77 -294 -$2,283
Vertex Pharmaceuticals Inc / Ma (VRTX) Arbuckle Stuart A EVP\Chief Commercial Officer $181.89 -2125 -$386,516
Zogenix, Inc. (ZGNX) Smith Michael P EVP, CFO, Treasurer, Sec. $50.00 -15000 -$750,000
Wiggins Mark C Dir $50.00 -6250 -$312,500

Index Watch



iShares NASDAQ Biotechnology Index



Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.